Summary
Raptor Pharmaceuticals Corp. (Raptor) is a biopharmaceutical company that develops and commercializes therapeutics for orphan diseases. The company’s lead product, Procysbi is a cysteamine bitartrate delayed-release capsule and is used in the treatment of a rare genetic disorder, nephropathic cystinosis. Its second product, Quinsair finds application in treating chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis. Raptor’s clinical stage product candidates include RP103, non-alcoholic fatty liver disease, and Convivia. The company offers preclinical programs such as HepTide, for the treatment of primary liver cancer; and ADO (cysteamine dioxygenase), for the treatment of diseases for which cysteamine is a medicine. Raptor is headquartered in Novato, California, the US.
Raptor Pharmaceutical Corp. (RPTP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Raptor Pharmaceutical Corp., Medical Devices Deals, 2010 to YTD 2016 10
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Raptor Pharma Acquires Rights to Quinsair from Triplex Pharma 13
Partnerships 14
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 14
Licensing Agreements 16
Raptor Pharma Enters Into Licensing Agreement With Satt Paca Corse For Rett Syndrome 16
Raptor Pharma Enters Into Licensing Agreement With Seattle Children's Research Institute 18
Raptor Pharma Enters Into Licensing Agreement With Universite Laval For IP Rights Related To Parkinson's Disease 20
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 21
Raptor Pharma Enters Into Licensing Agreement With University Of Iowa 22
Raptor Pharma Enters Into Licensing Agreement With Uni Pharma 23
Raptor Pharma Enters Into Licensing Agreement With Weizmann Institute And Niigata University 24
Equity Offering 26
Raptor Pharma Raises USD98 Million in Public Offering of Shares 26
Raptor Pharma Announces Public Offering Of Common Stock For US$40 Million 28
Raptor Pharma Completes Public Offering Of Common Stock For US$46 Million 30
Raptor Pharma Completes Private Placement For US$15 Million 32
Debt Offering 34
Raptor Pharma to Raise USD60 Million in Private Placement of 8% Senior Notes Due 2019 34
Acquisition 36
Raptor Pharma May Sell Itself 36
Raptor Pharmaceutical Corp. - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Raptor Pharmaceutical Corp., Deals By Therapy Area, 2010 to YTD 2016 8
Raptor Pharmaceutical Corp., Medical Devices Deals, 2010 to YTD 2016 10
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Raptor Pharma Acquires Rights to Quinsair from Triplex Pharma 13
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 14
Raptor Pharma Enters Into Licensing Agreement With Satt Paca Corse For Rett Syndrome 16
Raptor Pharma Enters Into Licensing Agreement With Seattle Children's Research Institute 18
Raptor Pharma Enters Into Licensing Agreement With Universite Laval For IP Rights Related To Parkinson's Disease 20
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 21
Raptor Pharma Enters Into Licensing Agreement With University Of Iowa 22
Raptor Pharma Enters Into Licensing Agreement With Uni Pharma 23
Raptor Pharma Enters Into Licensing Agreement With Weizmann Institute And Niigata University 24
Raptor Pharma Raises USD98 Million in Public Offering of Shares 26
Raptor Pharma Announces Public Offering Of Common Stock For US$40 Million 28
Raptor Pharma Completes Public Offering Of Common Stock For US$46 Million 30
Raptor Pharma Completes Private Placement For US$15 Million 32
Raptor Pharma to Raise USD60 Million in Private Placement of 8% Senior Notes Due 2019 34
Raptor Pharma May Sell Itself 36
Raptor Pharmaceutical Corp., Key Competitors 37
Raptor Pharmaceutical Corp., Key Employees 38
Raptor Pharmaceutical Corp., Subsidiaries 40
List of Figures
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Raptor Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Raptor Pharmaceutical Corp., Medical Devices Deals, 2010 to YTD 2016 10
